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Background—NADPH oxidase is believed to modulate arterial tone, but its role in humans is still unclear. The objective
of this study was to evaluate whether NADPH oxidase is involved in flow-mediated arterial dilation (FMD).
Methods and Results—Twenty-five patients with hereditary deficiency of gp91phox, the catalytic core of NADPH oxidase,
(X-CGD), 25 healthy subjects, and 25 obese patients matched for sex and age were recruited. FMD, platelet gp91phox,
serum levels of nitrite and nitrate as markers of nitric oxide generation, oxidized low-density lipoprotein, and urinary
excretion of isoprostanes as markers of oxidative stress were determined. Platelet gp91phox expression was downregu-
lated in X-CGD patients (1.00.8 mean fluorescence; P0.001) and upregulated in obese patients (4.12.2 mean
fluorescence; P0.01) compared with healthy subjects (2.91.7 mean fluorescence). Urinary excretion of isoprostanes
was reduced in X-CGD patients (41.733.3 pg/mg creatinine; P0.04) and increased in obese patients (154.491
pg/mg creatinine; P0.001) compared with healthy subjects (69.552.4 pg/mg creatinine). Obese patients had higher
serum oxidized low-density lipoprotein than healthy subjects (35.36.7 versus 24.89.8 U/L; P0.001) and X-CGD
patients (28.57.2 U/L; P0.001). X-CGD patients had significantly higher FMD (14.75.9%) compared with healthy
subjects (7.92.5%; P0.001); obese patients had lower FMD (5.33.0%; P0.028) compared with healthy subjects.
Serum nitrite and nitrate levels were significantly higher in patients with X-CGD (36.010.8 mol/L; P0.016) and
lower in obese patients (9.311.0 mol/L; P0.001) compared with healthy subjects (27.119.1 mol/L). Serum
nitrite and nitrate levels significantly correlated with FMD (Rs0.403, P0.001) and platelet gp91phox (Rs0.515,
P0.001). FMD inversely correlated with platelet gp91phox (Rs0.502, P0.001) and isoprostanes (Rs0.513,
P0.001).
Conclusion—This study provides the first evidence that, in humans, gp91phox is implicated in the modulation of arterial
tone. (Circulation. 2009;120:1616-1622.)
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Endothelial dysfunction is a hallmark of early atheroscle-rosis and predicts cardiovascular events in high-risk
cohorts, including the elderly and patients with hypertension,
coronary heart disease, or peripheral arterial disease.1–4 The
mechanism accounting for endothelial dysfunction is not
completely understood. Oxidative stress is believed to play an
important role in that it can influence activity and generation
of nitric oxide (NO), a potent vasodilator molecule produced by
endothelial cells.5 Several reactive oxidative species (ROS)
–generating enzymes, including myeloperoxidase, xanthine ox-
idase, and NADPH oxidase, may be implicated in arterial
dysfunction.6 Accordingly, experimental studies performed in
animal models suggest a pivotal role of NADPH oxidase in
modulating arterial tone.7–9 In particular, overexpression of
gp91phox, the catalytic subunit of NADPH oxidase (Nox2),
potentiates the hemodynamic response to angiotensin II.7
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However, a critical issue of these experimental studies is
their transferability to the comprehension of human athero-
sclerosis. In other words, it remains to be clarified whether
ROS-generating pathways have some role in the process of
human arterial dysfunction.
Chronic granulomatous disease (CGD) is a very rare genetic
disorder (1 in 1 000 000) characterized by life-threatening infec-
tious diseases resulting from defective activity of the innate
immune system caused by functional deficiency of NADPH
oxidase subunits.10 Among the NADPH oxidase subunits, the
functional deficiency of gp91phox (Nox2) is the most frequent
hereditary disorder (X-CGD).10
In a pilot study performed on 3 patients affected by gp91phox
genetic deficiency, we demonstrated that gp91phox activity
may play an important role in enhancing systemic and local
oxidative stress and modulating flow-mediated dilation
(FMD)11; the latter maximally reflects NO production by
endothelial cells.12 Nonetheless, the association reported in
that study was not conclusive because of the small sample
size and the lack of correction for major atherosclerotic risk
factors or other confounding variables. Thus, a multicenter
study enrolling a larger number of X-CGD patients recruited
by various Italian institutions was designed with the ultimate
goal of evaluating the involvement of gp91phox with FMD.
Methods
Study Population
We conducted a multicenter study in collaboration with the Italian
Primary Immunodeficiency Network. Of the 60 patients with CGD
registered in the national database,10 35 were not included in the
study because of the presence of acute infections, critical physical
conditions, hereditary NADPH oxidase deficiency unrelated to
gp91phox, or unwillingness to participate in the study. The remaining
25 patients who were gp91phox deficient and willing to participate in
the study were included.
Diagnosis of X-CGD was performed as previously described.10
All X-CGD patients were receiving itraconazole, trimethoprim, and
sulfamethoxazole.
Unpublished observations obtained by our department showed
that X-CGD patients had serum cholesterol levels 20% lower than
healthy subjects. Because this could represent a confounding factor,
25 control subjects matched for serum cholesterol, sex, and age were
identified and included in the study. Twenty-five patients affected by
obesity who were matched for gender and age were randomly
collected from the pediatric clinic and from the outpatient clinic of
our division at the “I Clinica Medica” of the Sapienza University of
Rome (the Table). Control populations were screened from routine
visits. For subjects 20 years of age, obesity was defined according
to body mass index–age-growth charts, which identify obesity as a
body mass index 95th percentile.13 Adult patients with a body
mass index 30 kg/m2 were considered obese.14
Subjects were excluded from the study if they had liver insuffi-
ciency, serious renal disorders (serum creatinine 2.8 mg/dL),
cancer, myocardial infarction, unstable angina, acute cerebrovascular
disease, or deep venous thrombosis; if they were being treated with
statins or antioxidant vitamins; or if they were current smokers. The
study was approved by the ethics committee. Each subject enrolled
gave informed consent to participate in the study. A substudy of
X-CGD patients (n7), healthy subjects (n7), and obese patients
(n7) who were matched for age was performed to investigate
platelet formation of NO and isoprostanes.
Blood Sampling
Between 8 and 9 AM, subjects underwent routine biochemical
evaluations, including fasting total cholesterol and glucose. After an
overnight fast (12 hours) and supine rest for at least 10 minutes,
blood samples were collected in Vacutainers (Vacutainer Systems,
Belliver Industrial Estate, Plymouth, UK) and centrifuged at 300g for
10 minutes to obtain supernatant, which was stored at 80°C until
use. Total cholesterol was measured with a routine enzymatic
colorimetric method on a Dimension RXL apparatus (Dade Behring
AG, Ziegelbrucke, Switzerland).
Table. Clinical Characteristics of X-CGD Patients, Healthy Subjects, and Obese Patients
X-CGD Patients (n25) P* HS (n25) P* Obese Patients (n25)
Age, y 16.69.5 … 16.69.5 … 16.69.5
Men, n 25 … 25 … 25
Systolic blood pressure, mm Hg 109.812.4 0.352 107.48.7 0.002 115.89.7
Diastolic blood pressure, mm Hg 68.09.2 0.064 72.47.5 0.698 71.610.0
Serum total cholesterol, mg/dL 126.720.0 0.483 133.513.8 0.001 197.255.5
Serum fasting blood glucose, mg/dL 76.78.0 0.98 79.97.0 0.421 81.47.9
BMI, kg/m2 18.12.9 0.052 19.63.0 0.001 25.93.8
Serum total protein, g/dL 7.10.9 0.529 7.30.5 0.637 7.20.9
Serum albumin, g/dL 4.50.4 0.101 4.70.3 0.196 4.50.6
Urinary isoprostanes, pg/mg creatinine 41.733.3 0.04 69.552.4 0.001 154.491
Serum ox-LDL, U/L 28.57.2 0.122 24.89.8 0.001 35.36.7
Serum CRP, mg/L† 2.0 (1.1–2.0) 0.332 1.4 (0.6–2.0) 0.937 1.4 (0.7–2.0)
Platelet gp91phox, mean fluorescence 1.00.8 0.001 2.91.7 0.010 4.12.2
Serum NOx, mol/L 36.010.8 0.016 27.119.1 0.001 9.311.0
IMT, mm 0.410.09 0.001 0.500.10 0.004 0.580.16
FMD, % 14.75.9 0.001 7.92.5 0.028 5.33.0
BMI indicates body mass index; CRP, C-reactive protein.
*Linear mixed-effects models.
†Expressed as median (interquartile range).
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Urinary Collection
Morning spot urine samples were collected from all participants
between 7 and 9 AM. Morning urine collected for F2-isoprostanes was
stored in 10-mL aliquots at 80°C until analysis.
Urinary 8-Iso-Prostaglandin F2 Assays
Urinary 8-iso-prostaglandin F2 (8-iso-PGF2) was measured by a
previously described and validated enzyme immunoassay method
(Cayman Chemical, Ann Arbor, Mich)15,16 and expressed as pico-
grams per milligram of creatinine. Intra-assay and interassay coef-
ficients of variation were 2.1% and 4.5%, respectively.
Oxidized Low-Density Lipoprotein and C-Reactive Protein
Serum levels of oxidized low-density lipoprotein (ox-LDL) and
C-reactive protein were measured by commercially available immu-
noassays (Tema Ricerca, Bologna, Italy). Intra-assay and interassay
coefficients of variation were 4.0% and 8.3% for ox-LDL and 9.5%
and 9.0% for C-reactive protein.
Nitrite and Nitrate Measurement
A colorimetric assay kit (Tema Ricerca) was used to determine the
NO metabolites nitrite and nitrate (NOx) in the serum and superna-
tant of platelet-rich plasma (platelets3108/mL) activated with
collagen (7 g/mL) at 37°C for 15 minutes as previously de-
scribed.17 Intra-assay and interassay coefficients of variation were
2.9% and 1.7%, respectively.
Platelet gp91phox Expression
Platelet gp91phox expression was analyzed as previously described.18
Briefly, blood samples were incubated with the unconjugated anti-
body anti-gp91phox, followed by an FITC-labeled donkey anti-goat
immunoglobulin G secondary antibody. For platelet detection, the
monoclonal antibody CD61-PE was used.
Samples were analyzed on an Epics XL-MCL cytometer (Coulter
Electronics, Hialeah, Florida) equipped with an argon laser at 488
nm. FITC was detected at 825 to 850 nm, PE at 875 to 900 nm.
Analysis was stopped automatically after the measurement of 50 000
events. Platelet gp91phox was expressed as mean fluorescence. Intra-
assay and interassay coefficients of variation were 1.0% and 0.2%,
respectively.
Platelet 8-Iso-PGF2 Assay
Citrated blood samples (ratio of blood to sodium citrate, 9:1) were
centrifuged for 15 minutes at 180g to obtain platelet-rich plasma.
Platelet-rich plasma was then centrifuged for 20 minutes at 300g to
obtain washed platelets, and the pellets were suspended in Tyrode
buffer to obtain a final platelet concentration of 3108/mL.
Platelet suspensions were incubated with or without collagen (7
g/mL) for 15 minutes at 37°C. After incubation, platelets were
pelleted 3 minutes at 300g with acid citrate dextrose.
Supernatants from stimulated and unstimulated platelets were
acidified to pH 3 with 1 mol/L HCl; 20 g internal standard
(8-iso-PGF2) was added. After addition of the internal standard, the
mixture was vortexed and applied to a C18 Sep-Pak column (Waters
Corp, Milford, Mass) preconditioned with 5 mL methanol and 5 mL
water (pH 3). The sample and subsequent solvents were eluted
through the Sep-Pak column with a 10-mL plastic syringe. The
column was then washed sequentially with 10 mL water (pH 3), 10
mL acetonitrile/water (15:85 vol/vol), and 10 mL heptane. The
isoprostanes were then eluted with 10 mL ethyl acetate/heptane
(50:50 vol/vol).19 The eluted samples were completely evaporated
under ultrahigh purity (99.9%). The samples, previously dissolved
with 10 L acetonitrile, were derivatized at various times (2 to 24
hours) with 40 L N,O-Bis(trimethylsilyl)trifluoroacetamide with
trimethylchlorosilane.
The 8-iso-PGF2 in derivatized samples was analyzed by a
PerkinElmer gas chromatograph (PerkinElmer, Waltham, Mass)
equipped with a flame ionization detector with a SPB5 wide-bore
column (Supelco, Bellefonte, Pa). Detector responses for 8-iso-pros-
taglandin and internal standard (8-iso-PGF2) were calculated by use
of an area integrator LC100 (PerkinElmer).
The carrier gas, helium, was set to a flow rate of 1 mL/min.
Derivatized samples (0.5 L) were injected into the gas chromato-
graph injection port. The column temperature was maintained at
170°C for 2 minutes, increased to 275°C at 15°C/min, and then held
at 275°C for 11 minutes. Finally, the temperature was raised to
300°C at 25°C/min and held for 10 minutes. 8-Iso-PGF2 content was
expressed as picomole per liter.
FMD and Carotid Intima-Media Thickness
Ultrasound assessment of FMD was investigated according to the
recently reported guidelines20 as previously described.21 The coeffi-
cient of variation for FMD measurements, obtained on 3 separate
occasions, was 12.5%.
Longitudinal ultrasonographic scans of the carotid artery were
obtained on the same day as the studies of the brachial artery
reactivity and included the evaluation of the right and left common
carotid arteries 1 cm proximal to the carotid bulb. Three measure-
ments of intima-media thickness (IMT) were obtained from the right
and left carotid arteries, respectively, and were averaged to deter-
mine the mean IMT for both sides combined. The coefficient of
variation for IMT measurements, obtained on 3 separate occasions, was
4.90%. FMD and IMT were performed with a 7.5-MHz linear-array
transducer ultrasound system (Sonomed, Lake Success, NY).
Statistical Analysis
We used linear mixed-effects models to compare means across
groups because the subjects in the study were matched by age and
sex. We used subject-specific random intercepts that were assumed
to arise from Gaussian distributions, with clusters of random effects
identified by the matched triplets (X-CGD, healthy subjects,
obese). The group indicators were included as fixed effects. Results
were further confirmed by nonparametric tests with the rank
transformation.
Data are presented as meanSD unless indicated otherwise. The
correlation analysis was carried out by Spearman rank correlation
test. Statistical significance was defined at P0.05. Statistical
analysis was performed with SPSS 13.0 for Windows (SPSS Inc,
Chicago, Ill).
Sample Size Determination
On the basis of data from a pilot study,11 we computed the minimum
sample size with respect to a 2-sample Student t test, considering a
clinically relevant difference for FMD variation to be detected
between the X-CGD patients and control subjects ||5%, SDs that
were homogeneous between groups (SDs3%), and type I error
probability of 0.05 and power 10.90. This resulted in a
minimum sample size of 9 subjects for each group. Sample size
calculations were performed with the nQuery Advisor software,
version 5.0, (Statistical Solutions, Saugus, Mass).
Results
Platelet expression of gp91phox and urinary excretion of
8-iso-PGF2 were downregulated in X-CGD patients
(P0.001 and P0.04) and increased in obese patients
(P0.01 and P0.001) compared with healthy subjects (the
Table). On the other hand, obese patients had higher serum
ox-LDL than healthy subjects and X-CGD patients
(P0.001), and X-CGD patients and healthy subjects had
similar values of serum ox-LDL (the Table). Furthermore,
X-CGD patients had significantly higher FMD (P0.001)
and serum levels of NOx (P0.016), markers of NO gener-
ation,21 compared with healthy subjects (Table 1). Con-
versely, obese patients had lower FMD (P0.028) and serum
NOx levels (P0.001) compared with healthy subjects (the
Table). IMT was significantly lower in patients with X-CGD
(P0.001) but significantly higher in obese individuals
(P0.004) compared with healthy subjects (the Table).
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No difference was found among the brachial resting vessel
size of the 3 groups (X-CGD, 2.90 mm [median] [interquartile
range 2.48 to 3.60]; healthy subjects, 3.27 mm [interquartile range,
2.69 to 3.75]; obese patients, 3.30 mm [interquartile range, 2.90 to
4.0]). However, we stratified patients according to the median
value observed in healthy subjects (3.27 mm) and found that
X-CGD patients with basal brachial artery diameter 3.27 mm
still showed significantly higher values of FMD (F13.0,
P0.001) than healthy subjects and obese patients (12.31.1%
versus 7.217% versus 5.43.6%, respectively).
Correlation analysis carried out by Spearman test showed
that FMD inversely correlated with platelet gp91phox expres-
sion (Rs0.502, P0.001; Figure 1A) and urinary excre-
tion of 8-iso-PGF2 (Rs0.513, P0.001). Moreover, FMD
directly correlated with serum NOx levels (Rs0.403,
P0.001; Figure 1B). The latter, in turn, significantly corre-
lated with platelet gp91phox (Rs0.515, P0.001; Figure
1C). IMT significantly correlated with FMD (Rs0.303,
P0.008), platelet gp91phox (Rs0.398, P0.001), NOx
(Rs0.433, P0.001), and urinary excretion of 8-iso-
PGF2 (Rs0.334, P0.003).
Finally, a substudy of age-matched X-CGD patients (n7),
healthy subjects (n7), and obese patients (n7) was per-
formed to investigate platelet formation of NO and isopros-
tanes. The clinical characteristics of enrolled subjects did not
differ from those of each subgroup study. After platelet
stimulation with collagen, patients with X-CGD had signifi-
cantly higher NO platelet production (35.510.0 mol/L)
compared with healthy subjects (22.512.0 mol/L,
P0.05), whereas obese individuals had lower NO produc-
tion compared with healthy subjects (11.22.5 mol/L,
P0.001; Figure 2A). Moreover, 8-iso-PGF2 formation in
platelets stimulated with collagen was lower in X-CGD
patients (124.4104.8 pmol/L; P0.05) and higher in obese
patients (851.8222.8 pmol/L; P0.001) compared with
healthy subjects (373.459.2 pmol/L; Figure 2B).
Discussion
This study provides the first evidence of an increased FMD in
patients with hereditary deficiency of gp91phox, suggesting a
role for this ROS-generating pathway in modulating arterial
tone. We also show that gp91phox is relevant for the isopros-
tane formation, given that both systemic and cellular forma-
tion of isoprostanes is significantly reduced in gp91phox-
deficient patients.
Because NADPH oxidase is the most important cellular
producer of superoxide anion,22 we investigated its role in the
formation of oxidant species such as isoprostanes and ox-
LDL. We found that only urinary excretion of isoprostanes
was significantly reduced in X-CGD patients compared with
healthy subjects. Isoprostanes are chemically stable free-
radical catalyzed products of arachidonic acid.23 So far, the
ROS-generating pathway eliciting isoprostane formation has
not been fully clarified. Here, we provide evidence that
gp91phox activation may play a pivotal role in the formation of
isoprostanes because patients with gp91phox knockout had
significantly reduced urinary excretion of isoprostanes.
Monocytes and platelets express gp91phox24,25 and produce
isoprostanes.26 Therefore, it is conceivable that the reduced
formation of isoprostanes reflects functional deficiency of
Figure 1. Linear regression analysis between FMD and gp91phox
(A), FMD and serum NOx gp91phox (B), and gp91phox and serum
NOx (C). The straight line represents the least-squares regres-
sion line.
Figure 2. NOx generation (A) and isoprostane formation (B) in
platelets stimulated with collagen (7 g/mL) in X-CGD patients,
healthy subjects (HS), and obese patients. Data are presented
as box plots. *P0.005; **P0.05.
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gp91phox in these cells. Consistent with this suggestion was the
significant reduced production of platelet isoprostanes from
patients with hereditary gp91phox deficiency. The contribution
of gp91phox by the cells from the artery wall is more compli-
cated because they produce superoxide anion not only by
gp91phox but also by other NADPH oxidase homologs.22
Recent studies demonstrated, in fact, the existence of several
NADPH oxidase homologues such as NOX1, NOX4, and
NOX5 in the cells of the artery wall, including endothelial
cells, smooth muscle cells, and adventitia cells.22
The presence of normal ox-LDL levels in X-CGD suggests
that other ROS-generating enzymes6 are involved in gener-
ating this marker of oxidative stress. An implication of this
finding is that the increase in ox-LDL in obese patients
should be attributed to other ROS-generating enzymes, which
is in agreement with our previously published observations of
a significant association between serum ox-LDL and myelo-
peroxidase, which suggested a role for this enzyme in
generating ox-LDL in vivo.27 Hence, in patients at risk of
cardiovascular disease such as those with obesity, the coex-
istence of high values of different markers of oxidative stress
suggests that 1 ROS-generating pathway is upregulated.
Several experimental studies have shown a pivotal role of
NADPH oxidase in modulating arterial tone.7–9 In an animal
model of NADPH oxidase knockout, an increased arterial
dilation compared with wild-type animals was observed.8,9,28
Furthermore, individuals with impaired dilation show an
overexpression of the NADPH oxidase subunit p47phox in
endothelial cells,29 but a cause-effect relationship between
FMD and NADPH oxidase activation was never demon-
strated. The results achieved in our human knockout model of
NADPH oxidase are consistent with animals studies in that
X-CGD patients had a higher FMD compared with healthy
subjects.
FMD is prevalently dependent on NO release from endo-
thelium,12 as also suggested by the significant correlation
between FMD and plasma nitroso compounds.30 Oxidative
stress seems to play a pivotal role in modulating FMD, likely
through altered NO bioavailability and biosynthesis.21 Ac-
cordingly, oxidative stress and FMD were inversely related in
patients with or without metabolic syndrome, and a 1-time
infusion of an antioxidant such as vitamin C was associated
with rapid restoration of arterial function.31 In this study,
NOx serum levels were higher in X-CGD patients and lower
in obese individuals compared with healthy subjects. The
direct correlation between NOx and FMD suggests a role for
NO in the enhanced arterial dilatation observed in X-CGD
patients. This suggestion is corroborated by the finding of a
lower NOx production in obese patients who had, in accor-
dance with a previous report,30 reduced FMD. We recognize,
however, that determination of NOx may be an unreliable
method to measure NO generation. This may depend on the
fact that NOx is influenced by many endogenous and exog-
enous factors, including dietary nitrate uptake, inhalation of
atmospheric nitrogen oxides, salivary formation, and renal
function.32 Even if we cannot exclude that such factors may
have influenced NOx serum levels, platelet production of NO
paralleled NOx in serum; thus, platelet generation of NOx
was increased in X-CGD, suggesting that cellular production
of NO was upregulated.
A potentially intriguing observation is the striking differ-
ence in FMD between healthy subjects (8%) and X-CGD
patients (15%). It is possible that during the evolution phase
of human beings, maximization of innate immune defense
mechanisms against infectious disease needed “upregulation”
of NADPH oxidase. Because NADPH oxidase is also ex-
pressed in the vascular wall, this could result in higher
vascular oxidative stress and ensuing lowering of the arterial
relaxation capability.
IMT is a noninvasive diagnostic measure of atherosclerosis
that correlates with histology and predicts cardiovascular
events, including myocardial infarction and stroke.33 IMT is
already increased in children with cardiovascular risk factors,
suggesting that it may be a good tool to measure premature
atherosclerosis.34 Previous studies have shown a direct cor-
relation between oxidative stress and IMT, suggesting a role
for oxidative stress in eliciting arterial damage.35,36 Indirect
evidence in support of the role of NADPH oxidase in
enhancing IMT has also been reported. In fact, in asymptom-
atic subjects free of overt atherosclerosis, phagocyte produc-
tion of superoxide anion significantly correlated with IMT,35
but direct evidence of NADPH activation was not provided.
In our X-CGD population, in whom gp91phox was functionally
deficient, we observed a significant decrease in IMT com-
pared with healthy subjects. However, these data should be
considered cautiously because the difference was very small
and may not firmly reflect a slower atherosclerotic progres-
sion in X-CGD patients.
This study has potential limitations. In particular, for
ethical reasons, we did not have the possibility of discrimi-
nating whether the enhanced arterial dilatation was dependent
on endothelium. Therefore, the role of NO in enhancing
arterial dilatation was not fully elucidated. However, FMD is
mostly dependent on endothelial release of NO.12 As a result,
it is possible that enhanced NO generation and/or bioactivity
resulting from low oxidative stress may be responsible for the
enhanced arterial dilatation of X-CGD patients. This hypoth-
esis is consistent with our previous report in which the
administration of N-nitro-L-arginine methyl ester, an inhibitor
of endothelial NO synthase, to adult X-CGD patients abol-
ished the increase in FMD.11 Reduced isoprostane formation
could be an alternative mechanism because isoprostanes are
vasoconstrictor molecules,23 although it has recently been
argued that isoprostanes may have such property in vivo.37
Despite the increase in NO generation, X-CGD patients
had normal arterial diameter and blood pressure. A possible
interpretation of this finding is that a resting increase in NO
(33% versus control) was insufficient to change such param-
eters. Thus, it is of note that in the group with obesity and
high blood pressure, NO generation was reduced by 65%
compared with control subjects.
Even if in obese patients gp91phox upregulation could
contribute to lower FMD, it is possible that other mechanisms
may contribute to lowering FMD in this setting. For instance,
ox-LDL, which was not influenced by gp91phox, could play a
role because its increase may directly affect NO38 and
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isoprostanes39; however, the relationship between ox-LDL
and FMD is still unclear.40–42
Finally, we must take into account the possibility that some
antibiotics may favorably affect FMD either directly, as in the
case of azithromycin,43 or indirectly through reduced serum
cholesterol levels.44,45 Reduced serum cholesterol levels, in
fact, are known to inversely correlate with FMD,18 but this
potential bias was eliminated in our study by the inclusion of
healthy subjects with comparable serum cholesterol. More-
over, no data on the effects of the antibiotics used by our
X-CGD patients (itraconazole, trimethoprim, and sulfame-
thoxazole) on FMD have been reported so far.
Conclusion
In this human knockout model of NADPH oxidase, arterial
dilatation was enhanced, thus providing the first evidence that
this ROS-generating pathway is implicated in modulating
arterial tone.
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CLINICAL PERSPECTIVE
Arterial dysfunction is a hallmark of early atherosclerosis and predicts cardiovascular events. The mechanisms accounting
for arterial dysfunction in humans are still unclear. NADPH oxidase is an enzyme that plays a major role in producing
reactive oxidant species into the cells. Reactive oxidant species formation is associated with inhibition of nitric oxide
activity and/or biosynthesis and may have deleterious effects in arterial function. We conducted a multicenter study to
measure flow-mediated dilation in 25 patients with chronic granulomatous disease (X-linked CGD) that is characterized by
hereditary deficiency of gp91phox, the catalytic subunits of NADPH oxidase. Compared with 25 healthy subjects and 25 obese
patients, X-CGD patients had lower oxidative stress, as assessed by urinary excretion of isoprostanes, and higher flow-mediated
dilation. Gp91phox expression increased progressively from X-CGD to obese patients, who showed lower flow-mediated dilation
compared with the other 2 groups. In the entire cohort, gp91phox expression inversely correlated with flow-mediated dilation. In
a subgroup study, platelet formation of nitric oxide was also determined. This analysis showed a progressive decrease in
nitric oxide from X-CGD to obese patients. Together, these findings suggest that vascular tone is modulated by NADPH
oxidase–generating reactive oxidant species with a mechanism involving nitric oxide generation. Systemic and cellular
measurement of NADPH oxidase expression could have a relevant impact on our understanding of the role of reactive
oxidant species in the initiation and progression of atherosclerosis. This could be a useful tool for exploring whether
inhibition of NADPH oxidase is able to halt the atherosclerotic process and its clinical sequelae.
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